17 April 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Scancell
to present at the Annual
Immuno-Oncology Summit Europe
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
announces that it will be presenting at the 8th
Immuno-Oncology Summit
Europe 2024. The Immuno-Oncology Summit Europe is a world-class event for professionals dedicated to showcasing
advancements and innovations in immuno-oncology for breakthrough
therapies, and is being held from 23-25 April 2024 in London,
UK.
Professor Lindy Durrant, Chief
Executive Officer of Scancell, will be speaking in the "Therapeutic
Cancer Vaccines" program, where emphasis on clinical studies will
be highlighted as part of a broader collection of talks furthering
understanding of immunological mechanisms of action, dosing and
delivery strategies as well as how such products can be combined
with checkpoint inhibitors. Her talk, titled "Clinical Update
on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine
Targeting Citrullination" will take place from 2:45 pm - 3:15 pm
BST on Tuesday 23 April 2024.
Professor Lindy Durrant, Chief Executive Officer of Scancell,
said: "I am pleased to be invited to
share this exciting data on SCIB1, Scancell's 'off the shelf'
ImmunoBody® cancer vaccine, which has demonstrated
positive efficacy data from the Phase 2 SCOPE trial for advanced
unresectable melanoma. I am also looking forward to presenting
early data from patients receiving Modi-1 as a monotherapy in range
of hard-to-treat solid tumours, which has shown good T cell
responses, safety and tolerability. Following on from AACR, there
has been significant interest in the clinical development of
therapeutic cancer vaccines, and I am excited to demonstrate the
progress Scancell has made in this class of
immunotherapies."
If you would like to arrange a
meeting with management, please contact commercial.enquiries@scancell.co.uk.
-ENDS-
|
For further
information, please contact:
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment
Banking)
|
|
|
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
WG Partners LLP
(Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope®
and ImmunoBody®
for vaccines and GlyMab® and
AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab®) or
enhances the potency of antibodies and their ability to directly
kill tumour cells
(AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/
